Enzymatica Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
22
- Stock Symbol
-
ENZY
- Investments
-
1
- Share Price
-
$0.30
- (As of Tuesday Closing)
Enzymatica General Information
Description
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
Contact Information
Website
www.enzymatica.se
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Devices and Supplies
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
- Ideon Science Park
- Scheelevägen 19
- 223 70 Lund
- Sweden
+46 046-286 00 00
Enzymatica Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.30 | $0.31 | $0.20 - $0.84 | $49.7M | 164M | 79.7K | -$0.04 |
Enzymatica Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 48,506 | 139,992 | 323,489 | 58,024 |
| Revenue | 5,281 | 6,666 | 12,065 | 6,482 |
| EBITDA | (5,870) | (4,447) | (649) | (3,669) |
| Net Income | (5,920) | (5,286) | (1,434) | (4,333) |
| Total Assets | 18,043 | 17,353 | 19,752 | 15,799 |
| Total Debt | 117 | 287 | 1,764 | 596 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Enzymatica Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Enzymatica Patents
Enzymatica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3749296-B1 | Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus | Active | 07-Feb-2018 | 0000000000 | |
| ES-2900661-T3 | Hydroxy-benzoic acid esters for use in the treatment of rhinoviruses | Active | 07-Feb-2018 | 0000000000 | |
| EP-3749296-A1 | Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus | Active | 07-Feb-2018 | 00000000000 | |
| GB-201801982-D0 | Novel treatments | Inactive | 07-Feb-2018 | 00000000000 | |
| US-20210213112-A1 | Esters of hydroxy-benzoic acids for use in the treatment of rhinovirus | Pending | 07-Feb-2018 | A61K38/4826 |
Enzymatica Executive Team (12)
Enzymatica Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 00000000 0 | Self | Board Member | 000 0000 |
Enzymatica Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Enzymatica Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Enzymatica Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 01-Apr-2016 | 0000000000 | 00.00 | Pharmaceuticals | 0000000 0 |
Enzymatica ESG
Risk Overview
Risk Rating
Updated November, 18, 2022
37.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.0
Percentile
Pharmaceuticals
Subindustry
00 of 431
Rank
00.00
Percentile
